Reduced SMAD2/3 Activation Independently Predicts Increased Depth of Human Cutaneous Squamous Cell Carcinoma

    February 2018 in “ Oncotarget ”
    Aidan M. Rose, Lindsay C. Spender, Christopher D. Stephen, Alastair Mitchell, William Rickaby, Susan E. Bray, Robert Dawe, Jasbani H.S. Dayal, Karin J. Purdie, Catherine A. Harwood, Charlotte M. Proby, Irene M. Leigh, Philip J. Coates, Gareth J. Inman
    Studysummary This study observed that reduced activation of SMAD2/3 proteins in cutaneous squamous cell carcinoma tissue compared to adjacent tissue may indicate a tumor suppressor role in disease progression.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study found that reduced activation of SMAD2/3 independently predicted increased depth and severity of human cutaneous squamous cell carcinoma (cSCC). Analysis of 249 tissue samples revealed that lower levels of phosphorylated SMAD2 and SMAD3 were significantly correlated with thicker and more invasive tumors. These findings suggested that SMAD2/3 could serve as potential biomarkers for assessing the aggressiveness of cSCC, supporting the hypothesis that TGF-β signaling acts as a tumor suppressor in cSCC. The research highlighted the need for further investigation into TGF-β signaling pathways in cSCC progression.
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results